New immunotherapy cocktail aims to outsmart biliary cancer
NCT ID NCT07654530
First seen Jun 17, 2026 · Last updated Jun 21, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two immunotherapy drugs (sintilimab and ipilimumab) plus chemotherapy (albumin-bound paclitaxel and gemcitabine) as a first treatment for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. The study aims to see if this new mix can shrink tumors better than current standard treatments. About 107 participants will receive the drug combination, and researchers will track how many respond and how long they live without the cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCERS (BTC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sintilimab, ipilimumab, albumin-bound paclitaxel, and gemcitabine
What this could lead to
If successful, this combination could offer a more effective first-line treatment for advanced biliary tract cancer, potentially improving response rates and survival beyond current chemoimmunotherapy.
What could go wrong
This is an early-phase (Phase 2) trial with only 107 participants, so results may not be definitive. The drug combination may cause significant side effects, and the benefit over existing therapies is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.